Primapur

2023: Start of Production

In February 2023, the Ural Medsintez Plant"" announced its readiness to completely replace imported drugs for IVF c. As Russia part of these plans, the company has already begun production of one of these drugs - recombinant follicle-stimulating hormone (FSH) for human treatment infertility "Primapur."

"Primapur" is used in an in vitro fertilization (IVF) program to induce follicle growth in the ovaries. This technology allows you to obtain the required number of mature eggs ready for fertilization for effective IVF treatment.

Drug for the treatment of infertility "Primapur"

Now we are producing a drug for women's reproductive health - a recombinant follicle-stimulating hormone, which the Medsintez Plant fully imports, since in Russia there are only imported follicle-stimulating hormone drugs. If its supplies stop, then IVF will not be possible in Russia in principle. Also, in the production of human chorionic gonadotropin, there is a shortage of raw materials, we will also produce this hormone by biotechnology, this is also an import substitution project, "Alexander Petrov, chairman of the board of directors of Zavod Medsintez LLC, told TASS on February 19, 2023.

According to him, one of the main functions of the enterprise is import substitution. Thus, the Medsintez Plant began its work by replacing imported infusion solutions. And in 2006, a governor's program was proposed to create an insulin plant on the basis of the Medsintez Plant, which the company fulfilled, Petrov noted.

He added that by February 2023, the plant is developing two more drugs for women's reproductive health that are not produced in Russia. What products are in question is not specified.^[1]

Notes